259 related articles for article (PubMed ID: 21372226)
1. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
3. Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanism.
Allensworth JL; Sauer SJ; Lyerly HK; Morse MA; Devi GR
Breast Cancer Res Treat; 2013 Jan; 137(2):359-71. PubMed ID: 23225169
[TBL] [Abstract][Full Text] [Related]
4. Differential response of head and neck cancer cell lines to TRAIL or Smac mimetics is associated with the cellular levels and activity of caspase-8 and caspase-10.
Raulf N; El-Attar R; Kulms D; Lecis D; Delia D; Walczak H; Papenfuss K; Odell E; Tavassoli M
Br J Cancer; 2014 Nov; 111(10):1955-64. PubMed ID: 25314064
[TBL] [Abstract][Full Text] [Related]
5. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
[TBL] [Abstract][Full Text] [Related]
6. Novel SMAC-mimetics synergistically stimulate melanoma cell death in combination with TRAIL and Bortezomib.
Lecis D; Drago C; Manzoni L; Seneci P; Scolastico C; Mastrangelo E; Bolognesi M; Anichini A; Kashkar H; Walczak H; Delia D
Br J Cancer; 2010 Jun; 102(12):1707-16. PubMed ID: 20461078
[TBL] [Abstract][Full Text] [Related]
7. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J
PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027
[TBL] [Abstract][Full Text] [Related]
8. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
[TBL] [Abstract][Full Text] [Related]
9. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
10. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
[TBL] [Abstract][Full Text] [Related]
11. Small-molecule IAP antagonists sensitize cancer cells to TRAIL-induced apoptosis: roles of XIAP and cIAPs.
Finlay D; Vamos M; González-López M; Ardecky RJ; Ganji SR; Yuan H; Su Y; Cooley TR; Hauser CT; Welsh K; Reed JC; Cosford ND; Vuori K
Mol Cancer Ther; 2014 Jan; 13(1):5-15. PubMed ID: 24194568
[TBL] [Abstract][Full Text] [Related]
12. RIP1 is required for IAP inhibitor-mediated sensitization for TRAIL-induced apoptosis via a RIP1/FADD/caspase-8 cell death complex.
Abhari BA; Cristofanon S; Kappler R; von Schweinitz D; Humphreys R; Fulda S
Oncogene; 2013 Jul; 32(27):3263-73. PubMed ID: 22890322
[TBL] [Abstract][Full Text] [Related]
13. Smac peptide potentiates TRAIL- or paclitaxel-mediated ovarian cancer cell death in vitro and in vivo.
Mao HL; Pang Y; Zhang X; Yang F; Zheng J; Wang Y; Liu P
Oncol Rep; 2013 Feb; 29(2):515-22. PubMed ID: 23151974
[TBL] [Abstract][Full Text] [Related]
14. IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα.
Shekhar TM; Miles MA; Gupte A; Taylor S; Tascone B; Walkley CR; Hawkins CJ
Oncotarget; 2016 Jun; 7(23):33866-86. PubMed ID: 27129149
[TBL] [Abstract][Full Text] [Related]
15. Cellular inhibitor of apoptosis 1 (cIAP-1) degradation by caspase 8 during TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis.
Guicciardi ME; Mott JL; Bronk SF; Kurita S; Fingas CD; Gores GJ
Exp Cell Res; 2011 Jan; 317(1):107-16. PubMed ID: 20951133
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
Yang J; McEachern D; Li W; Davis MA; Li H; Morgan MA; Bai L; Sebolt JT; Sun H; Lawrence TS; Wang S; Sun Y
Mol Cancer Ther; 2011 Apr; 10(4):658-69. PubMed ID: 21282353
[TBL] [Abstract][Full Text] [Related]
17. Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.
Yang D; Zhao Y; Li AY; Wang S; Wang G; Sun Y
Breast Cancer Res Treat; 2012 May; 133(1):189-99. PubMed ID: 21901386
[TBL] [Abstract][Full Text] [Related]
18. IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.
Perimenis P; Galaris A; Voulgari A; Prassa M; Pintzas A
BMC Cancer; 2016 Aug; 16():624. PubMed ID: 27520705
[TBL] [Abstract][Full Text] [Related]
19. Cooperative TRAIL production mediates IFNα/Smac mimetic-induced cell death in TNFα-resistant solid cancer cells.
Roesler S; Eckhardt I; Wolf S; Fulda S
Oncotarget; 2016 Jan; 7(4):3709-25. PubMed ID: 26788912
[TBL] [Abstract][Full Text] [Related]
20. Smac mimetics and type II interferon synergistically induce necroptosis in various cancer cell lines.
Cekay MJ; Roesler S; Frank T; Knuth AK; Eckhardt I; Fulda S
Cancer Lett; 2017 Dec; 410():228-237. PubMed ID: 28923396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
